Alluvi, previously known as LY3414901, represents a significant advancement in obesity management. This dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) target https://alluvihealthcare442740.aioblogs.com/96091137/alluvi-a-deep-exploration-into-the-medication-s-promise